Abbott develops and sells medical technologies and health solutions across cardiovascular care, diabetes management, diagnostics, nutrition, and neuromodulation. Cardiovascular devices help manage heart health; diabetes products enable glucose monitoring; diagnostic tests provide timely results; nutrition products support health; neuromodulation therapies target the nervous system to relieve pain or aid movement. It differentiates itself with a broad, integrated portfolio and a focus on accessibility and affordability of technologies worldwide. Its goal is to improve global health and well-being by delivering life-changing technologies that are accessible and affordable.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Professional Development Budget
Wellness Program
Abbott and Berry Street partner to expand personalized nutrition support for consumers seeking better metabolic health. * Partnership combines Abbott's Lingo continuous glucose monitor with Berry Street's insurance-covered registered dietitian support, helping consumers translate glucose insights into healthier behaviors * Research shows registered dietitian-led medical nutrition therapy can improve glucose control and cardiometabolic health outcomes, highlighting the power of combining glucose data plus human expertise[1] ABBOTT PARK, Ill. and NEW YORK, Sept. 23, 2026 /PRNewswire/ - Abbott (NYSE: ABT) and Berry Street today announced an exclusive partnership to help people take a more proactive approach to nutrition and long-term health. The partnership brings together Lingo, Abbott's consumer biowearable that provides personal glucose insights, with live nutrition coaching from Berry Street, one of the nation's largest insurance-covered nutrition care platforms, helping consumers turn metabolic insights into meaningful action. Lingo is an over-the-counter continuous glucose monitor (CGM) for individuals 18 years of age or older who are not using insulin and want to make informed decisions about their health. By showing how food, movement and stress affect glucose, Lingo can help people make small, science-backed adjustments that can lead to measurable improvements in overall health and well-being. Through the partnership, Berry Street* and Lingo users can now: * Access registered dietitians specially trained on Lingo and continuous glucose monitors * Receive personalized nutrition recommendations informed by their glucose trends * Meet virtually through convenient one-to-one appointments Metabolic health challenges continue to affect millions of Americans. According to the Centers for Disease Control and Prevention, more than 115 million US adults have prediabetes, yet approximately 80% are unaware they have it.[2] Left unaddressed, prediabetes can increase the risk of developing Type 2 diabetes, heart disease and stroke. "At Abbott, we believe the future of health lies in giving people the tools and support they need to understand their bodies and take action," said Olivier Ropars, divisional vice president of Abbott's Lingo business. "By partnering with Berry Street, we're combining the advanced biosensing technology of Lingo with expert nutrition guidance to help people make informed nutrition and lifestyle decisions that can support healthy habits over time." Published research from the American Journal of Clinical Nutrition has shown that registered dietitian-led nutrition therapy can improve glucose control, weight management, cholesterol levels and other cardiometabolic markers, including among people with prediabetes.[3] [4] "For too long, nutrition guidance has relied on broad recommendations that may not reflect how an individual's body actually responds to food," said Noah Kotlove, chief executive officer and co-founder of Berry Street. "The combination of continuous glucose insights and registered dietitian expertise creates a more personalized approach to nutrition. Together with Lingo, we're helping consumers move beyond guesswork and build sustainable habits rooted in a deeper understanding of their health." The partnership with Berry Street builds on Abbott's commitment to helping people improve their health through science-backed nutrition innovation. Lingo adds to that legacy by providing personal metabolic insights that help consumers make more informed nutrition and lifestyle decisions. * Berry Street nutrition services are in-network with more than 1,250 health plans, with 96% of people paying no out-of-pocket costs. Coverage depends on the specific details of an individual's insurance plan. Frequently Asked Questions What is Lingo? Lingo is Abbott's over-the-counter continuous glucose monitoring (CGM) system designed for individuals 18 years and older who are not using insulin. Lingo provides ongoing glucose insights, helping people understand how food, exercise, sleep and stress affect their glucose levels and metabolic health. By turning real-time glucose data into personalized insights, Lingo is designed to help people make informed lifestyle choices in support of their personal wellness goals. What will this partnership bring to Lingo and Berry Street users? The partnership will combine Abbott's Lingo glucose insights with Berry Street's registered dietitians trained on Lingo, who will interpret glucose data into personalized nutrition plans tailored to an individual's health goals. How can a Lingo user access the Berry Street nutritionists and how much will it cost? A Lingo user will be directed to sign up for Berry Street nutritionist services on the Lingo website and from email communications directly from Lingo. Berry Street appointments are virtual, making them accessible wherever you are in the US. Berry Street also accepts coverage from more than 1,250 health plans, so 96% of clients pay $0 out-of-pocket. Coverage depends on the specific details of an individual's insurance plan. How can a Berry Street user access their glucose data and how much will it cost? For the first time and through this exclusive partnership, Berry Street users can now obtain Lingo at a discounted price, enabling them to gain a better understanding of how their behavior and lifestyle changes can affect their glucose. By seeing how their glucose is reacting to food, exercise, sleep and stress, Berry Street users can make continuous and ongoing modifications as they work to address and improve their health concerns. Additionally, Berry Street dietitians can view their patient's glucose data providing additional personalized guidance and coaching. Berry Street users will receive a 15% discount on 4-week Lingo plans. Why is tracking glucose important for people who do not have diabetes? Glucose is the body's primary source of energy and plays a central role in overall metabolic health. Even in people without diabetes, glucose levels are influenced by everyday factors such as nutrition, physical activity, sleep and stress. By understanding glucose patterns, people can better assess how daily habits affect their bodies and make choices that support energy, well-being and long-term health. Tracking these patterns over time may also help identify risks for chronic conditions, including prediabetes, which affects more than 115 million U.S. adults. About Lingo The Lingo Glucose System is intended for users 18 years and older, not on insulin. It is not intended for diagnosis of diseases, including diabetes. The Lingo program does not guarantee that everyone will achieve the same results as individual responses may vary. Consult your healthcare professional before making changes to your diet or exercise regimen or if you have an eating disorder or a history of eating disorders. Lingo can be purchased at hellolingo.com, Amazon, Walmart (in-store and online), Walgreens, BestBuy.com and Publix. Lingo is available in the US and the UK. The Lingo app is now available for download for Android through the Google Play Store and for iOS on the Apple App Store. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Its 122,000 colleagues serve people in more than 160 countries. About Berry Street Berry Street is on a mission to transform how Americans eat through nutrition therapy. Berry Street's platform connects individuals needing evidence-based nutrition care with an expansive network of Registered Dietitians and AI-powered tools. From weight management, diabetes, and heart health to kidney disease, maternal health, and 30+ other conditions, Berry Street's clinical team delivers personalized nutrition interventions tailored to each patient's unique physiological and psychological needs, improving outcomes and reducing total cost of care. Berry Street works with some of the largest health plans, as well as leading health systems and innovative care management companies to serve diverse populations across all 50 states. Visit berrystreet.co to learn more. SOURCE Abbott For further information: Abbott Media: Monica Ma, [email protected], Abbott Financial: Michael Comilla, [email protected], Berry Street Media: Richard Fu, [email protected]
California joins $385 million Abbott settlement over infant formula claims. California Attorney General Rob Bonta announced on Sep. 21 that California, along with 39 other states and the federal government, has reached a $385 million settlement with Abbott Laboratories to resolve allegations related to the manufacture of certain powder infant formula and nutritional therapy products. Under the agreement, Abbott will pay $348.7 million to the United States for False Claims Act allegations and $35.5 million to participating states for Medicaid-related claims. California is set to receive over $15 million in restitution and other recoveries. "Today's settlement holds Abbott accountable for its misrepresentation of its product and production," said Bonta. "These state and federal regulations are in place to ensure we can provide the highest quality of care and products to mothers and their young children. This settlement sends the necessary message that these regulations aren't suggestions. My office is committed to ensuring all products we provide for Californians are truly as high quality as they claim to be." The U.S. Department of Agriculture funds and regulates the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), which supplies nutritional support including infant formula; more than half of all infant formula purchased nationally is paid for through WIC funds. Many state Medicaid programs also cover specific powder infant formulas. The settlement resolves allegations that between 2018 and 2022, Abbott caused false claims by failing to comply with statutory, regulatory, and contractual requirements during manufacturing processes - allegedly putting products at risk of microorganism contamination affecting reliability, quality, and safety when purchased with taxpayer dollars. The resolved claims remain allegations only; there has been no determination of liability against Abbott Laboratories. Rob Bonta leads the California Attorney General's office, which serves as the state's chief law enforcement authority across California by enforcing laws related to civil rights, consumer protection, environmental justice, public safety initiatives, transparency tools such as the OpenJustice data portal, and policy advancement in economic security issues - all as part of its constitutional role within California's executive branch, according to the official website.
Ambry Genetics pays $700K HIPAA fine in phishing breach. Settlement Comes After Firm Paid Nearly $12.3M to Settle Civil Claim for Same Hack Marianne Kolbasuk McGee (HealthInfoSec) - September 21, 2026 A California genetics testing laboratory has agreed to pay a $700,000 HIPAA fine and implement improvements to its security practices in the wake of a 2020 phishing attack that compromised the sensitive information of 225,000 patients. The company settled a civil class action claim for $12.25 million in 2023 for the same breach. Ambry Genetics' HIPAA resolution agreement with the U.S. Department of Health and Human Services announced Thursday is also among the company's latest legal woes. In a separate case, Ambry Genetics' parent company - Tempus AI - is facing proposed class action litigation alleging that the company violated the genetic privacy and medical-confidentiality statutes and other laws of several states when Tempus acquired Ambry in 2025 and transferred the sensitive genetic information of "hundreds of thousands, if not millions" of Ambry's patients to train Tempus' artificial intelligence models without the patients' consent (see: Health AI Firm Faces Lawsuits Over DNA Use, Disclosure). Ambry's HIPAA settlement last week with HHS' Office for Civil Rights resolves an investigation into a January 2020 phishing incident Ambry reported to the agency in March 2020 that affected 225,370 people. Information potentially accessed in the hack included patient names, dates of birth, health insurance information, medical information, and for some patients, Social Security numbers, diagnosis information and other information. HHS OCR's investigation found Ambry violated several provisions of the HIPAA security rule. Violations included failing to conduct an accurate and thorough HIPAA security risk analysis; failing to implement procedures for terminating access to electronic protected health information when the employment of or other arrangement with a workforce member ends; and failing to assign a unique name or number for identifying and tracking user identity in systems containing ePHI. Ambry Genetics did not immediately respond to ISMG's request for comment on the company's settlement. Besides paying the $700,000 HIPAA fine, Ambry also agreed to implement a corrective action plan, which HHS OCR will monitor for two years, to improve the company's HIPAA compliance and the security of patient data. That includes conducting an accurate and thorough HIPAA security risk analysis; developing and implementing a risk management plan to mitigate risks identified in the risk analysis; developing and revising its policies to comply to the HIPAA rules; implementing unique user identification in all its IT systems containing ePHI; and ensuring all workers are trained on the company's HIPAA security rule policies and procedures. In 2023, Ambry settled proposed federal class action litigation for the same breach, for $12.25 million. Under that settlement, Ambry agreed to pay up to $10,000 to each eligible class member in claims showing documented out-of-pocket costs traced to the breach, and also three years of credit and identity monitoring. Ambry also agreed to implement certain remedial and enhanced security measures to bolster its data security practices. Hacking incidents involving other genetics testing and related companies appear to be on the rise in recent weeks and months. That includes a June hack in Texas-based genomics testing firm Baylor Genetics affecting 2.8 million people, including sensitive patient information such as test results and employee data (see: Breach Roundup: China Calls for Stronger AI Oversight). Other recent hacks include the theft of data from clinical testing laboratory and medical device maker Abbott Laboratories and its cancer diagnostics business Exact Sciences (see: Patient Sues Abbott Labs, Exact Sciences in Data Theft). Cybercrime gang ShinyHunters and another gang, ShadowByt3$, each claimed to steal data - including AI models - from Abbott's Exact Sciences unit (see: Craneware, Abbott Probe Separate Health Data Theft Incidents). Also, cybercrime gang FulcrumSec in August claimed it leaked on its darkweb site two large caches of data the group claims it stole in a June attack on Novo Nordisk. The latest data dump allegedly includes the Danish drug maker's "complete enterprise Hugging Face AI and machine learning ecosystem" (see: Extortion Gang Leaks Novo Nordisk 'AI and ML Ecosystem'). "Theft of genetic information supercharges the risks to victims," said regulatory attorney Paul Hales of the Hales Law Group. "Genetic information, unique to each individual's health and family history, poses risks that go far beyond routine identity theft, especially in this age of unregulated AI," said Hales, who is not involved in the Ambry litigation. "Consider how nefarious actors could use this information." "Effective AI regulation is essential, among other things, to protect the privacy and security of individuals' health information." The proposed class action lawsuit facing Ambry parent company Tempus AI seeks damages and an injunction against further allegedly unauthorized use, transfer, disclosure or commercialization of plaintiffs and class members' genetic information.
Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments Advances Abbott's mission to make healthcare more accessible and give people more control over their health...
Casa Grande baby formula plant tied to $384m settlement over unsafe production. Abbott Laboratories, the corporation behind Similac, did not admit any wrongdoing. by Kieran Hadley The government's Special Supplemental Nutrition Program for Women, Infants and Children (WIC) buys about half the baby formula in the U.S., awarding regional monopolies to a handful of large suppliers. Photo: Enfamil Formula at Kroger. Abbott Laboratories, the company behind popular infant formula brand Similac, settled a lawsuit this week over claims alleging unsanitary conditions at its production sites, including at its facility in Casa Grande. The lawsuit alleged that Abbott knowingly sold its formula to US government food assistance programs such as Medicaid and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) despite being aware of contamination risk at its facilities. Families enrolled in WIC account for over half of baby-formula consumption in the United States. In 2022, Abbott recalled several of its products and temporarily shut down its facility in Sturgis, Michigan, after some infants fell ill and died of cronobacter infection after consuming formula produced there. The Sturgis complaints focused on haphazard repair of roof leaks and a lack of testing for dangerous bacteria. The settlement also mentioned its Casa Grande facility, which is Casa Grande's fourth-largest employer, employing about 750 workers. According to the Associated Press, a 2023 inspection of the Casa Grande facility found numerous lapses in contamination safety protocols and detections of cronobacter. The AP also noted "nearly two dozen complaints of confirmed cronobacter, salmonella or other infections in infants who had been fed formula made at the plant." Abbott maintains that no unopened can of formula ever tested positive for cronobacter. The Department of Justice hailed the settlement as a victory for American families. "No company should be gambling on the health and safety of our Nation's infants by allowing unsanitary conditions to persist at a facility manufacturing baby formula," said Associate Attorney General Stanley E. Woodward, Jr. in a statement. Abbott agreed to pay over $384 million to settle the lawsuit. $69 million will go to the three whistleblowers who filed the qui tam lawsuit, and $36 million will go to specific states' Medicaid and WIC claims. The rest will go to the federal government. By posting comments, you agree to its Connect. About. Support. Compliance. AZPM is a service of the University of Arizona and its broadcast stations are licensed to the Arizona Board of Regents who hold the trademarks for Arizona Public Media and AZPM. Azpm respectfully acknowledge the University of Arizona is on the land and territories of Indigenous peoples.